Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 26, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
July 17, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept...
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
June 27, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 03, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 26, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
Corcept Therapeutics Announces Final Results of Tender Offer
April 05, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Preliminary Results of Tender Offer
April 03, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Initiates CATALYST Clinical Trial
March 28, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
March 06, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
February 28, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...